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 Frequency of extensively drug-resistant tuberculosis 
in Pakistan increased from 1.5% in 2006 to 4.5% in 2009 
(p<0.01). To understand the epidemiology, we genotyped 
selected strains by using spoligotyping, mycobacterial in-
terspersed repetitive units–variable number of tandem re-
peats, and IS6110 restriction fragment length polymorphism 
analysis.
Emergence and spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis 
(TB) are facilitated by inadequate detection and treatment 
(1). TB detection and treatment are more diffi cult in coun-
tries, like Pakistan, that are facing complex emergencies, 
including humanitarian crises and confl icts (2). Published 
data report an increasing prevalence of MDR TB and emer-
gence of XDR TB strains in Pakistan (3).
This study documents an increasing trend of XDR re-
sistance within MDR TB isolates in Pakistan. To obtain 
better insight into the epidemiology of these strains, we 
genotyped selected XDR TB strains by using spoligotyp-
ing, mycobacterial interspersed repetitive units–variable 
number of tandem repeats (MIRU-VNTR), and IS6110 re-
striction fragment length polymorphism (RFLP) analysis. 
This study was approved by the Ethics Review Committee 
of the Aga Khan University and conducted at the Aga Khan 
University Hospital, Karachi, Pakistan.
The Study
The Aga Khan University Hospital laboratory receives 
specimens from >180 collection units located in major cit-
ies and towns in Pakistan. Specimens for TB cultures are 
requested by physicians as required and received through 
passive specimen collection. Past treatment history is usually 
not available and thus could not be included in this study. My-
cobacterium tuberculosis was isolated from the specimens 
by using Lowenstein-Jensen and MGIT (Becton Dickinson, 
Franklin Lakes, NJ, USA) media. It was then identifi ed by 
using the BACTEC NAP TB differentiation test (Becton 
Dickinson), growth in para-nitrobenzoic acid–containing 
media, nitrate reduction, and niacin accumulation (4).
We performed susceptibility testing by using an agar 
proportion method on enriched Middlebrook 7H10 medi-
um (BBL Microbiology Systems, Cockeysville, MD, USA) 
at the following concentrations: rifampicin 1 μg/mL, isoni-
azid 0.2 μg/mL, streptomycin 2 μg/mL and 10 μg/mL, and 
ethambutol 5 μg/mL. Pyrazinamide sensitivity was deter-
mined by using BACTEC 7H12 medium, pH 6.0, at 100 
μg/mL (BACTEC PZA test medium, Becton Dickinson). 
MDR TB strains were further tested with capreomycin 10 
μg/mL, ciprofl oxacin 2 μg/mL, ethionamide 5 μg/mL, ami-
kacin 5μg/mL, and kanamycin 6 μg/mL. Reference strain 
M. tuberculosis H37Rv was used as a control with each 
susceptibility testing batch (5). M. tuberculosis drug-sus-
ceptibility testing is validated by the Supranational Labo-
ratory Network of the World Health Organization (www.
who.int/drugresistance/tb/en/).
MDR TB was defi ned as resistance to at least isoniazid 
and rifampicin. XDR TB was defi ned as resistance to qui-
nolones and to 1 of the injectable second-line drugs in addi-
tion to MDR. Randomly selected isolates were confi rmed as 
XDR TB by using the GenoType MTBDRsl assay (HAIN 
Lifesciences, Nehren, Germany). XDR TB isolates were 
stored at –80°C. Stored XDR TB strains were revived for 
genotyping; 57 isolates that grew were used for spoligotyp-
ing and MIRU-VNTR typing (3 isolates from 2006, 5 from 
2007, 19 from 2008, and 30 from 2009).
DNA was extracted by using the cetyltrimethylam-
monium bromide method (6). Spoligotyping was per-
formed by using a commercially available kit provided 
by Isogen Life Science (De Meern, the Netherlands). 
Spoligotyping based on the 43 spacers of the DR region 
of M. tuberculosis complex was performed by using prim-
ers DRa 5′-GGTTTTGGGTCTGACGAC-3′ and DRb 
5′-CCGGAGAGGGGACGGAAAC-3′ as described (7). 
Negative and positive controls, including template-free 
PCR–amplifi ed reaction mixture and M. tuberculosis 
H37Rv DNA, were used with each spoligotype blot.
Data extracted from the computerized information sys-
tem of the hospital were transferred to the statistical software 
SPSS version 14.0 (SPSS, Chicago, IL, USA). Frequencies 
with percentages were computed for each year. We used χ2 
for trend analysis to assess resistance trends over the study 
period. A p value <5% was considered signifi cant.
The spoligotyping results were entered in the BioNu-
merics Software version 3.5 (Applied Maths Program, 
Biosystematica, Ceredigion, UK). A dendrogram was gen-
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erated by using the unweighted pair–group method with 
arithmetic averages calculation. The spoligotypes were 
compared with the most prevalent M. tuberculosis sub-
families as identifi ed by the World Spoligotyping Database 
SpolDB4.0 of Pasteur Institute of Guadeloupe (www.pas-
teur-guadeloupe.fr/tb/bd_myco.html) (8), which includes 
>40,000 isolates split into 1,030 shared types and >3,530 
orphan profi les.
The isolates were genotyped by PCR amplifi cation of 
15 MIRU-VNTR loci by using standard methods as de-
scribed (9). Sizes of the PCR fragments and assignment 
of the various VNTR alleles were also determined by us-
ing standard protocol for gel electrophoresis (www.geno-
screen.com). All reactions were performed in duplicate by 
using standard positive and negative controls supplied in 
the MIRU-VNTR validation kit.
IS6110 RFLP of M. tuberculosis strains were per-
formed by standardized methods (10). Briefl y, XDR TB 
strains were recovered on LJ medium. DNA was extracted 
from the strains by standard methods (6,10). PvuII-digest-
ed DNA was subjected to agarose gel electrophoresis and 
Southern blotting. DNA fi ngerprinting was performed 
by hybridization with the IS6110 by using the enhanced 
chemiluminescence method (Amersham Biosciences, Pis-
cataway, NJ, USA).
During 2006–2009, a total of 9,523 M. tuberculosis 
strains were isolated, including 3,682 (38.7%) MDR TB 
strains. Although the MDR TB rate remained constant 
(Table 1), the XDR TB rate (expressed as a percentage of 
MDR TB isolated in a year) showed a signifi cant increase. 
The XDR TB strains were from specimens received from 
23 cities; the largest numbers were from Karachi (22), 
Hyderabad (13), and Peshawar (12). Mean ± SD age of 
patients with XDR TB was 37 ± 14 (range 16–80) years; 
57.15% were men and 42.85% women.
Diversity of XDR TB strains among the 57 iso-
lates genotyped is shown by spoligotyping (Table 2) and 
MIRU-VNTR analysis. Spoligotyping data points to the 
predominance of strains belonging to the Central Asian 
Strain (CAS) 1 family (n = 24 [42.1%]). Overall CAS 
strains included CAS1_KILI ST21 (n = 2); CAS1_DE-
HLI ST25 (n = 1); CAS1, ST26 (n = 24); CAS1_DEHLI 
ST428 (n = 1); CAS1_DEHLI ST794 (n = 1); CAS1_DE-
HLI ST1198 (n = 3); and CAS1_DEHLI ST1401 (n = 1). 
The second largest family comprised the Beijing (ST1) 
genogroup (n = 5 [8.8%]). Four (7%) strains of T family 
(ST53 and ST804) and 2 strains of U family (ST346) were 
also identifi ed. Additional XDR TB strains included 1 (2%) 
strain each of EAI (ST11) and X (ST200). Furthermore, 
1 new unmatched cluster and 9 unmatched orphan types 
were also recognized. MIRU-VNTR patterns of all XDR 
TB strains were different, indicating a lack of clustering 
among the strains studied. Randomly selected strains pres-
ent in CAS1 (ST26, n = 6) and Beijing (ST1, n = 3) clusters 
were subjected to IS6110 RFLP typing. RFLP patterns of 
each of these strains also differed, further confi rming a lack 
of clustering among the XDR TB strains studied.
Conclusions
This study demonstrated a rising XDR-TB trend in 
Pakistan and raises concerns despite the fact that Pakistan’s 
2009 XDR rate (4.5%) of MDR TB is below the global av-
DISPATCHES
1474 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 9, September 2010
Table 1. Frequency of multidrug-resistance and extensively drug-resistance among Mycobacterium tuberculosis isolates, Pakistan, 
2006–2009*
Year 
No. M. tuberculosis
isolates MDR isolates, no. (%)
MDR + ciprofloxacin-resistant 
isolates, no. (% of total MDR) 
Total no. XDR 
isolates
XDR as % of total 
MDR 
2006 1,917 728 (38) 131 (18) 11 1.5
2007 2,019 782 (39) 168 (21.5) 17 2.2
2008 2,584 991 (38) 356 (36) 32 3.2
2009 3,003 1,181 (39) 512 (43) 53† 4.5
*MDR, multidrug resistant; XDR, extensively drug resistant.  
†By trend analysis (p value for trend <0.01).  
Table 2. Spoligotype distribution of 57 extensively drug-resistant 
strains of Mycobacterium tuberculosis, Pakistan, 2006–2009* 
Genogroup and shared type No. (%) isolates Overall % 
CAS 57.9
 ST21 2 (3.5) 
 ST25 1 (1.8) 
 ST26 24 (42.1) 
 ST428 1 (1.8) 
 ST794 1 (1.8) 
 ST1198 3 (5.3) 
 ST1401 1 (1.8) 
Beijing 8.8
 ST1 5 (8.8) 
EAI3 1.8
 ST11 1 (1.8) 
U 1.8
 ST346 2 (3.5) 
T1 7.0
 ST53 1 (1.8) 
 ST804 3 (5.3) 
X3 1.8
 ST200 1 (1.8) 
Unmatched cluster 2 (3.5) 3.5
Orphan types 9 (15.8) 15.8
*ST, spoligotype; CAS, Central Asian strain; EAI, East African Indian 
strain. 
XDR TB, Pakistan
erage (6.6%–23.7%) (11). Genotyping data are comparable 
with those from earlier studies (12,13), suggesting domi-
nance of CAS1 strains. The fact that Beijing family strains 
were 9% of XDR TB isolates vs. 3% prevalence in the 
overall MDR TB reported in this population (13) suggests 
that Beijing strains are associated with drug resistance in 
Pakistan and adjacent countries (14).
Furthermore, the fi nding that the XDR TB strains in 
our study were genetically diverse argues against dissemi-
nation of 1 particular genogroup responsible for drug resis-
tance and supports the concept that XDR TB in Pakistanis 
is likely to be a consequence of inadequate treatment of 
TB. The challenging sociopolitical situation in Pakistan is 
likely to exacerbate this public health problem. Emergency 
measures are required to avoid an exponential rise in drug-
resistant TB in the country and the region. We recommend 
that increased XDR TB rates in this area be considered not 
just of national concern but also be recognized as a regional 
public health issue requiring introduction of cooperative 
and support measures aimed at limiting the spread of drug-
resistant TB within southern Asia. 
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